The CagriSema study results are a setback for the Danish drugmaker in its efforts to regain ground lost to Eli Lilly in the obesity-drug market.
Source link
Novo Nordisk Shares Plunge After Obesity Drug Fails to Beat Zepbound
Date:
More like thisRelated
Getty Images Plans to End Shutterstock Deal After U.K. Imposes Conditions
Getty Images plans to terminate its merger agreement with...
Kawhi traded to Raptors: Grades, reaction, Clippers’ next steps
Zach KramJun 30, 2026, 04:30 PM ETCloseZach Kram is...
A golden ticket for AI: Netflix re-creates Gene Wilder’s voice for new ‘Willy Wonka’ show
Call it pure AI-magination. Limited time: Save 25% on...
Birthright citizenship ruling: what each Supreme Court justice said
It was not a unanimous decision. The Supreme Court...